OX40 is a potent immune-stimulating target in late-stage cancer patients. - Wikidata - awgldk - TriplyDB

OX40 is a potent immune-stimulating target in late-stage cancer patients.

OX40 is a potent immune-stimulating target in late-stage cancer patients.

http://www.wikidata.org/entity/Q34381674

about

Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer Cancer immunotherapy: the beginning of the end of cancer?Cancer stem cells and immunoresistance: clinical implications and solutions Natural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer Immunotherapy Viro-immune therapy: A new strategy for treatment of pancreatic cancer Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect Immune checkpoint inhibitors: therapeutic advances in melanoma Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications Strategies for combining immunotherapy with radiation for anticancer therapy Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Immunotherapy in the treatment of non-small cell lung cancer The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination Mechanisms of action of therapeutic antibodies for cancer The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.Current clinical trials testing the combination of immunotherapy with radiotherapy.Targeting CD8+ T-cell tolerance for cancer immunotherapy.New Immunotherapy Strategies in Breast Cancer.Combination immunotherapy: a road map.Immune modulation for cancer therapy.Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies.OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy.PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity.Optimizing Timing of Immunotherapy Improves Control of Tumors by Hypofractionated Radiation Therapy.Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab C-Myc regulation by costimulatory signals modulates the generation of CD8+ memory T cells during viral infection.OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer.Emerging therapeutic targets in metastatic progression: A focus on breast cancer.The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1.OX40+ Regulatory T Cells in Cutaneous Squamous Cell Carcinoma Suppress Effector T-Cell Responses and Associate with Metastatic Potential.Regulatory T cells with multiple suppressive and potentially pro-tumor activities accumulate in human colorectal cancer Combinational Immunotherapy with Allo-DRibble Vaccines and Anti-OX40 Co-Stimulation Leads to Generation of Cross-Reactive Effector T Cells and Tumor Regression.RNA Sequencing Analysis Reveals Interactions between Breast Cancer or Melanoma Cells and the Tissue Microenvironment during Brain Metastasis.Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".MEDI1873, a potent, stabilized hexameric agonist of human GITR with regulatory T-cell targeting potential The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy.

P2860

Q26740288-4078E5EF-75BF-4575-B052-F7635E3BECB4 Q26752277-ED2E91AB-CEFA-476A-A798-4793B731BA28 Q26769757-EFD39E4D-3919-45C7-81BF-67A83FD91B54 Q26772347-58AD73E2-2090-49BF-AC12-873A2E087B11 Q26774641-36364782-4756-43B1-9BE7-53AEF602BABB Q26775578-3D41D0CF-D1B1-416C-AC3F-4DAB1B9F36E2 Q26775591-C5E47C94-C3E0-4341-B060-B4EDF24FDF99 Q26779221-247A3B86-5195-43A1-BC1B-6B61EE309C25 Q26796675-98143F4A-9090-4272-9393-7834738370CD Q26996518-6FA1E57A-47BC-43B7-A09F-46C024DCEBF2 Q27000382-83D95188-5898-4F0C-964E-907D8532302C Q27022789-5AC73281-95DE-46F7-A59D-A13916F6CF8D Q28068378-78FD182E-1106-4AA0-A285-02DE293CCE7C Q28385366-79578DDE-4461-443A-B269-FE3E393B79F6 Q30248748-96A7B273-6E5A-4F03-BD42-EED86C240B18 Q30356447-BBDEC013-AC47-4D80-997D-A05129C65EDC Q34432692-85B4448F-EBEC-4031-BED5-BD523DF64F82 Q34549227-30705BD3-6E99-4094-A72F-55E167E7C0BD Q34552128-03F49732-45E1-4592-92D6-4CF818B6B354 Q34686944-C863B0F0-6F6B-4C24-BEBB-570EF3601C03 Q35107009-0C0D6506-94F3-4376-BFB1-DEB4ED552685 Q35118177-C761AEE1-784B-4E17-8099-0266E8854046 Q35611447-A7BBD0BF-6CFD-476E-A10A-BEF56D30B8A8 Q36046884-C3410880-08E6-418C-866D-DCD87617ACDC Q36203023-0AB394A7-D255-4D7D-A4E2-F6B9301A9611 Q36531690-723A1E52-0209-467B-A6DF-F384477246E2 Q36545813-E7BCAA91-3E48-4A75-BE8D-11EFA1EFB11A Q36664213-6DB67F15-7EE4-4805-ABA8-FB1F8C69F7AC Q36854062-23A96CFD-EF29-490B-8FC7-63E1875E1169 Q36940326-1F1F7674-ACAD-4E96-852D-2E62D9FC8F84 Q37114367-C3A0E0BC-CA4B-4A5A-8DEA-B390BA28D990 Q37158481-7022B286-E34A-455A-AEB5-FB6B37A3E62C Q37180457-9E8473F4-027F-410B-B1E8-7824E8CA7F1B Q37222138-DBA664B1-2401-4911-A326-9B6EB6597BCB Q37428061-DDAB63D7-873A-47E5-B096-5F97B88ACB7A Q37624944-9E46FA07-D0B9-41B6-8D5E-81C277C2C0A1 Q37652790-F787C272-4250-4E8D-9BA1-E6D31FAFDEAA Q37670024-9BA77F93-AA85-4D45-B2D7-E0CB61CA841B Q37741582-B500D2AC-F258-4B3D-81DB-B8834AE8486A Q38081999-51E0A891-3597-4CA3-B0AF-647415397172

P2860

OX40 is a potent immune-stimulating target in late-stage cancer patients.

http://www.wikidata.org/entity/Q34381674

description

2013 nî lūn-bûn

@nan

2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@ast

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@en

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@nl

type

label

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@ast

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@en

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@nl

prefLabel

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@ast

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@en

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@nl

P1433

Q34381674-E6921EEC-EF37-476B-AAC9-53568338B6FA

P1476

Q34381674-A53B723C-FADB-4589-A1C8-DB69A65305AF

P2093

Q34381674-21046455-ED5C-4D80-8D23-866BB4BCAB9E

Q34381674-3464DDF7-89C0-4FA0-B0D8-AF483C462674

Q34381674-426B7EFC-E761-48D0-B8FA-527169A8DF84

Q34381674-44153C80-7E80-4B22-8AD4-CE86BBA36789

Q34381674-44F6456A-AB99-436B-9E59-6D19684AFF50

Q34381674-572F9C02-1633-4DED-98B4-10F30C81111C

Q34381674-57B87F1D-F18A-4A71-9B92-99C8B97F92C2

Q34381674-6A07AB48-12CD-4649-A2F1-29877E5DFF5E

Q34381674-6EBDB267-2CDC-4829-B3CD-487311329F17

Q34381674-779500BE-3B4F-4941-850F-35E6C3F56BB1

P2860

Q34381674-03410814-DBA6-44A2-96E4-00B822C42C68

Q34381674-06BA9806-BAB0-4EA3-B2F7-C9D1B8A67AEF

Q34381674-07FC78BA-B918-4C2C-B805-51967F098A43

Q34381674-09FEDD54-F341-412E-B588-E197DF793951

Q34381674-1F69DF38-0174-4AF0-BF07-9E060F8C2B67

Q34381674-21B93742-80FD-439A-942E-785E7776E5AB

Q34381674-3774F1E5-E345-4648-9D49-DDF5234F51DC

Q34381674-4074BA9C-2D46-4654-A188-F46586BDAB8E

Q34381674-426979A8-FB05-477E-8516-B249A61360A4

Q34381674-448B5283-AE81-4416-82A9-C6E3EDB5E393

P304

Q34381674-9D4C57E4-95AC-46F4-845D-65DEFD897615

P31

Q34381674-1BAB32A3-613D-4AAF-BC67-F289621FA4F9

P356

Q34381674-F8E26755-6480-425A-8B72-1344EF630EEC

P407

Q34381674-D0EA24B5-0D9C-458E-9496-84110B5C9687

P433

Q34381674-E7078FCF-39FD-4B91-962D-16070B21E548

P478

Q34381674-60FAA597-772A-4483-B706-D5DC25ED8944

P577

Q34381674-2C81CC64-4405-465A-83C7-A505919D30F5

P5875

Q34381674-8A57BFB2-4B3B-4110-B5A3-33E60EF82A97

P698

Q34381674-C38C536A-AE34-4355-B899-668DC2F9C106

P932

Q34381674-CB3DA935-CDCC-46C1-864C-77986570B08C

P356

0008-5472.CAN-12-4174

P1433

Cancer Research

P1476

OX40 is a potent immune-stimulating target in late-stage cancer patients.

@en

P2093

Andrew D Weinberg

http://www.w3.org/2001/XMLSchema#string

Bernard A Fox

http://www.w3.org/2001/XMLSchema#string

Brenda Fisher

http://www.w3.org/2001/XMLSchema#string

Brendan D Curti

http://www.w3.org/2001/XMLSchema#string

Daniel Haley

http://www.w3.org/2001/XMLSchema#string

Edwin Walker

http://www.w3.org/2001/XMLSchema#string

Eric Bernstein

http://www.w3.org/2001/XMLSchema#string

Iliana Gonzalez

http://www.w3.org/2001/XMLSchema#string

Joshua Walker

http://www.w3.org/2001/XMLSchema#string

Kevin Floyd

http://www.w3.org/2001/XMLSchema#string

P2860

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade

Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts

Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data.

Exhaustive expansion: A novel technique for analyzing complex data generated by higher-order polychromatic flow cytometry experiments.

P304

7189-7198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-12-4174

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258214129

http://www.w3.org/2001/XMLSchema#string

P698

24177180

http://www.w3.org/2001/XMLSchema#string

P932

3922072

http://www.w3.org/2001/XMLSchema#string